J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
BridgeBio enters the pan-KRAS game
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
Imunon looks for an IL-12 Ovation
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
